Aquavit Holdings is thrilled to announce the filing of its Investigational New Drug Application with the FDA for its revolutionary intradermal injection of botulinum toxin, Dermatox™ (aqubotulinumtoxinA).
This cutting-edge biotechnology has already received regulatory approval across multiple countries in Asia, South America, and the Middle East, and is now undergoing Phase III clinical trials in many other territories. With its advanced intradermal injection, Aquavit is leading the way in the development of groundbreaking botulinum toxin applications.
AqubotulinumtoxinA is being studied in a phase II/III clinical trial, SAFESQIN, to assess its safety and efficacy in temporarily improving mild to moderate facial and neck wrinkles, as well as skin quality, in adults younger than 65. Join us as we explore the potential of this promising new treatment!
For over three decades, botulinum toxins have been used to improve both aesthetic and therapeutic indications. Now, Aquavit is leading the way in pioneering the first FDA approved intradermal injection of botulinum toxin to reduce the appearance of fine lines and improve skin quality on the face and neck. This groundbreaking advancement promises to revolutionize the way we look and feel.
The global botulinum toxin market is projected to reach an incredible USD 7.9 billion by 2026, and Aquavit is leading the charge. Combining AqubotulinumtoxinA and its patented microchannel technology (AQT-001), Aquavit is poised to make a huge impact in this space and revolutionize the industry. In 2021, the market was valued at USD 4.6 billion and the future looks bright for Aquavit.
We are thrilled to announce the upcoming clinical trials of Dermatox™, a revolutionary new product in the dermatology space. With its cutting-edge technology, we are confident that Dermatox™ will be a game-changer in this ultra-competitive field. As CEO of Aquavit, Sobin Chang MPH, is passionate about this new product and believes it will be a great success.
For the first time ever, physicians have the ability to safely and effectively treat the delicate layers of the skin to reduce fine lines and improve skin quality on the entire face and neck area. This revolutionary technology offers a new way to achieve a more youthful and rejuvenated look.
Dermatox™ is set to revolutionize the way we treat skin quality, becoming the first approved botulinum toxin for improving overall skin quality. This groundbreaking treatment option is a step up from existing botulinum toxins, which are limited to intramuscular injections for moderate to severe lines in a specific area. According to CMO of Aquavit, Churlsu Kwon MD PhD MPH, Dermatox™ is a game changer in the world of skincare.
About Aquavit Holdings
Aquavit Holdings is a biotechnology company revolutionizing healthcare with personalized applications of botulinum toxins. By using this powerful toxin in innovative ways, Aquavit Holdings is helping to improve patients’ health, maximize the efficiency of our medical community, and support the pharmacoeconomics of payers. Through this cutting-edge approach, Aquavit Holdings is bringing a brighter future to healthcare.